Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
Select a cancer below for additional information on ORP active trials at NCCN Member Institutions.
| Aarti Bhatia, MD, MPH | Yale Cancer Center/Smilow Cancer Hospital | Single-Arm Phase II Trial of Dual Inhibition of EGFR with Afatinib and Cetuximab with Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck |
| Yasir Elamin, MD | The University of Texas MD Anderson Cancer Center | Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR) |
| Pasi Janne, MD | Dana-Farber/Brigham and Women's Cancer Center/ Massachusetts General Hospital | A Phase 2 Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer |
| Joseph Treat, MD | Fox Chase Cancer Center | TH-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked |
| Martin McCarter, MD | University of Colorado Anschutz Medical Campus | Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR) |
| Scott Plotkin, MD | Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center | Phase 2 study of neratinib for adolescents and adults with neurofibromatosis 2 and progressive NF2-related neoplasms: a sub-study of the INTUITT-NF2 platform-basket trial (NCT04374305) |
| Gurkamal Chatta, MD | Roswell Park Comprehensive Cancer Center | A Phase IB Clinical Trial: Improving Outcomes with Androgen Pathway Inhibitors by targeting DNA methyltransferase Activity |